ReviewNeurology. Clinical practice2021
The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension: Body Weight.
Review in Neurology. Clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.The journal of headache and pain · 2025Pooled it
- The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.Brain : a journal of neurology · 2023Trial
- Visual Field Pointwise Analysis of the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT).Translational vision science & technology · 2023Trial
- Association of Amount of Weight Lost After Bariatric Surgery With Intracranial Pressure in Women With Idiopathic Intracranial Hypertension.Neurology · 2022Trial
- Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranial hypertension.European journal of endocrinology · 2022Trial
- Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension.The journal of headache and pain · 2021Trial
- Structural MRI Biomarkers of Intracranial Pressure in IIH: Linking Optic Nerve Sheath, Pituitary Morphology, and Hormonal Changes.Clinical neuroradiology · 2026Article
- "Just lose weight": weight-based medical bias and experiential expertise in intracranial hypertension.Frontiers in psychiatry · 2026Article
- Idiopathic Intracranial Hypertension in Children and Adolescents with Obesity: A Narrative Review.Children (Basel, Switzerland) · 2025Review
- Headache and GLP-1 receptor agonists: when medications are therapeutic and when they contribute to the symptom.Arquivos de neuro-psiquiatria · 2025Review
- Identifying predictors and assessing causal effect on hypertension risk among adults using Double Machine Learning models: Insights from Bangladesh Demographic and Health Survey.PLoS computational biology · 2025Article
- Non-invasive assessment of intracranial compliance in idiopathic intracranial hypertension: an MRI-ICP study.Eye (London, England) · 2025Article
- Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study.Endocrinology, diabetes & metabolism · 2025Article
- Covert cerebrospinal fluid dynamics dysfunction: evolution from conventional to innovative therapies.Frontiers in neurology · 2025Review
- The effect of GLP-1 agonist on idiopathic intracranial hypertension: a systematic review and meta-analysis.Therapeutic advances in neurological disorders · 2025Article
- Metabolic Dysfunction in Idiopathic Intracranial Hypertension: Current Theories and Updates.Aging and disease · 2024Review
- Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist In Patients with Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study.medRxiv : the preprint server for health sciences · 2024Article
- Managing idiopathic intracranial hypertension in the eye clinic.Eye (London, England) · 2024Review
- Idiopathic Intracranial Hypertension After Abrupt Cessation of Medication: A Case Report of Abrupt Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Cessation and Review of the Literature.Current pain and headache reports · 2024Review
- Does a Healthy Weight Body Mass Index at Onset of Idiopathic Intracranial Hypertension Change the Outcomes? A United Kingdom Prospective Cohort Study.Neuro-ophthalmology (Aeolus Press) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIdiopathic intracranial hypertension (IIH) prevalence increased in conjunction with rising obesity rates. Here, we highlight the importance of weight management in IIH and introduce glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) as potential treatment strategy for IIH. RECENT
findingsWeight gain is a risk factor for IIH, and weight loss (via any treatment strategy) plays a key role in IIH management. GLP-1 is an incretin secreted by the distal small intestine in response to a meal. GLP-1 RAs have been shown to improve glycaemic control (no hypoglycaemia) and lower body weight in patients with and without type 2 diabetes. The choroid plexus has been found to express GLP-1 receptors, and treatment with a GLP-1 RA significantly reduces CSF secretion in vitro and intracranial pressure (ICP) in rodents. SUMMARY: New research evaluating the pathophysiology of IIH supports GLP-1 RA as a potential treatment for IIH via weight loss dependent and independent mechanism to directly reduce ICP.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.